Haemolytic anaemia and thrombocytopenia following phenobarbital therapy for alcohol withdrawal
Authors:
- 17 September 2026
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 19 (9) , e275025
Abstract
Drug-induced immune haemolytic anaemia (DIIHA) is a rare but potentially life-threatening condition. Phenobarbital is increasingly used for the management of alcohol withdrawal; however, haematologic toxicity is infrequently reported. We describe a man in his 50s admitted for alcohol withdrawal who developed acute anaemia and thrombocytopenia shortly after initiation of phenobarbital. Laboratory findings were consistent with haemolysis, including undetectable haptoglobin and indirect hyperbilirubinaemia, although the direct antiglobulin test was negative. Alternative causes were excluded. Following discontinuation of phenobarbital, haematologic parameters improved rapidly. This case highlights a probable instance of phenobarbital-associated haemolysis with thrombocytopenia and emphasises the importance of recognising DIIHA even in the absence of a positive antiglobulin test.Keywords
This publication has 8 references indexed in Scilit:
- Hospital-Wide Implementation, Clinical Outcomes, and Safety of Phenobarbital for Alcohol WithdrawalJAMA Network Open, 2025
- Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort studyBlood Advances, 2024
- Phenobarbital-induced autoimmune haemolytic anaemia, thrombocytopenia and peripheral lymphadenomegaly due to reactive lymphoid hyperplasia in a catJournal of Feline Medicine and Surgery Open Reports, 2022
- Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single CentreTransfusion Medicine and Hemotherapy, 2015
- Drug-induced immune hemolytic anemiaHematology-American Society Hematology Education Program, 2009
- Phenobarbital-Associated Bone Marrow Aplasia: A Case Report and Review of the LiteratureActa Haematologica, 2008
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981
- Megaloblastic Anaemia Due to PhenobarbitoneBMJ, 1960